Allogene Therapeutics (ALLO) Net Cash Flow (2018 - 2026)

Allogene Therapeutics has disclosed Net Cash Flow across 9 years of filings, most recently posting -$21.4 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$21.4 million, up 34.75% year-over-year; the trailing twelve-month figure through Mar 2026 was -$12.1 million (down 41.5% YoY), and the FY2025 annual result was -$23.5 million, down 196.46% from the prior year.
• Net Cash Flow came in at -$21.4 million for Q1 2026 at Allogene Therapeutics, down from $13.9 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $119.6 million in Q2 2024 to a low of -$119.4 million in Q3 2024.
• The 5-year median for Net Cash Flow is -$12.5 million (2022), against an average of -$8.4 million.
• Peak annual rise in Net Cash Flow reached 288.89% in 2023, while the deepest fall reached 294.36% in 2023.
• Allogene Therapeutics' Net Cash Flow stood at -$12.5 million in 2022, then soared by 211.69% to $13.9 million in 2023, then jumped by 72.4% to $24.0 million in 2024, then sank by 42.15% to $13.9 million in 2025, then plunged by 254.11% to -$21.4 million in 2026.
• The last three Net Cash Flow figures came in at -$21.4 million (Q1 2026), $13.9 million (Q4 2025), and -$14.5 million (Q3 2025), per Business Quant data.